Biological therapies for asthma

Biological therapies for asthma

Five to 10% of asthma patients remain symptomatic and/or have asthma attacks despite adequate inhaled and systemic therapy. Eosinophilic, type 2 airway inflammation is seen in half of these patients with severe asthma. There is now convincing evidence that type 2 inflammation drives susceptibility t...

Bibliografski detalji
Glavni autori:	Couillard Castonguay, S, Pavord, I
Daljnji autori:	Janes, S
Format:	Book section
Jezik:	English
Izdano:	Elsevier 2021

Slični predmeti

Fractional exhaled nitric oxide non-suppression in asthma
od: Couillard Castonguay, S
Izdano: (2021)

Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype OxfoRd Asthma attaCk risk scaLE (ORACLE)
od: Couillard Castonguay, S, i dr.
Izdano: (2022)

Fluticasone furoate: CAPTAIN of fluticasones in type 2 inflammatory asthma
od: Couillard, S, i dr.
Izdano: (2022)

Asthma in pregnancy: An update
od: Couillard, S, i dr.
Izdano: (2020)

How I do it: workup of severe asthma
od: Couillard, S, i dr.
Izdano: (2021)

Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma
od: Trivedi, A, i dr.
Izdano: (2016)

Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis
od: Oliver, ME, i dr.
Izdano: (2021)

Type 2 inflammation and biological therapies in asthma: targeted medicine taking flight
od: Howell, I, i dr.
Izdano: (2023)

Emerging biologics in severe asthma
od: Pavord, I, i dr.
Izdano: (2016)

Pharmacokinetic optimisation of inhaled steroid therapy in asthma.
od: Pavord, I, i dr.
Izdano: (1993)

Blood eosinophils, fractional exhaled nitric oxide, and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling
od: Couillard, S, i dr.
Izdano: (2022)

A proof-of-concept scale to predict asthma attacks: the OxfoRd Asthma attaCk risk ScaLE (ORACLE)
od: Couillard, S, i dr.
Izdano: (2021)

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
od: Couillard, S, i dr.
Izdano: (2021)

Biomarkers predicting response to corticosteroid therapy in asthma.
od: Brightling, C, i dr.
Izdano: (2005)

Biological Therapy for Asthma
od: Resti Yudhawati, i dr.
Izdano: (2021-01-01)

Antibiotics for asthma attacks: masking uncertainty
od: Ramakrishnan, S, i dr.
Izdano: (2021)

Asthma phenotypes.
od: Pavord, I
Izdano: (2012)

Cough and asthma.
od: Pavord, I
Izdano: (2004)

Biological therapy of severe bronchial asthma
od: I. Melnychaiko, i dr.
Izdano: (2023-06-01)

Blood eosinophils, fractional exhaled nitric oxide and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling
od: Richard Beasley, i dr.
Izdano: (2022-04-01)

Biological therapy for severe asthma
od: Silvano Dragonieri, i dr.
Izdano: (2021-08-01)

Management of asthma in adults: current therapy and future directions.
od: Green, R, i dr.
Izdano: (2003)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
od: Moran, AM, i dr.
Izdano: (2020)

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma
od: Moran, A, i dr.
Izdano: (2020)

Asthma guidelines.
od: Green, R, i dr.
Izdano: (2000)

Single inhaler maintenance and reliever therapy (SMART) in general practice asthma management: where are we?
od: Thomas, M, i dr.
Izdano: (2012)

Step 4: stick or twist? A review of step 4 asthma therapy
od: Slater, M, i dr.
Izdano: (2016)

Cycling biologic therapy for severe asthma
od: S. Hamada, i dr.
Izdano: (2022-01-01)

Biologic Therapy and Severe Asthma in Children
od: Daniele Russo, i dr.
Izdano: (2021-06-01)

Azithromycin in uncontrolled asthma
od: Brusselle, G, i dr.
Izdano: (2017)

Asthma in elite athletes
od: Martin, N, i dr.
Izdano: (2010)

Controversies in allergy: should severe asthma with eosinophilic phenotype always be treated with anti-IL-5 therapies
od: Pavord, I, i dr.
Izdano: (2019)

Severe T2-high asthma in the biologics era: European experts' opinion
od: Pavord, I, i dr.
Izdano: (2019)

Asthma control, airway responsiveness and airway inflammation.
od: Pavord, I
Izdano: (2009)

Non-eosinophilic asthma and the innate immune response.
od: Pavord, I
Izdano: (2007)

Mepolizumab, quality of life, and severe eosinophilic asthma.
od: Pavord, I
Izdano: (2017)

FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma
od: Couillard, S, i dr.
Izdano: (2021)

Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing
od: Couillard, S, i dr.
Izdano: (2022)

Stability of inflammatory phenotypes in asthma.
od: Green, R, i dr.
Izdano: (2012)

Eosinophils in asthma and airway hyperresponsiveness.
od: Brightling, C, i dr.
Izdano: (2004)